genovis ab (GENO:Stockholm)
genovis ab (GENO) Snapshot
|
Open
kr4.49
|
Previous Close
kr4.50
|
|
|
Day High
kr4.49
|
Day Low
kr3.54
|
|
|
52 Week High
06/14/13 - kr4.50
|
52 Week Low
09/6/12 - kr2.47
|
|
|
Market Cap
66.3M
|
Average Volume 10 Days
3.9K
|
|
|
EPS TTM
kr-1.82
|
Shares Outstanding
15.8M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
genovis ab (GENO) Related Businessweek News
No Related Businessweek News Foundgenovis ab (GENO) Details
Genovis AB (publ) develops and provides nanoparticles and services for biomedical imaging. The company’s products in antibody fragmentation include FragIT kit technology to produce F(ab')2 or Fab' antibody fragments; FabRICATOR, a genetically modified enzyme that splits antibodies into two parts, a Fab fragment and an Fc fragment; and FragIT microspin columns, which allows fragmentation of IgG into F(ab’)2 and Fc fragment. Its products in antibody deglyosylation comprise IgGZERO, a protein that splits off sugar molecules that occur naturally in antibodies; deGlycIT microspin columns, which allows deglycosylation of IgG; and Mass Spec kit that contains the FabRICATOR and IgGZERO enzyme to perform deglycosylation and fragmentation of IgG molecules. The company’s magnetic nanoparticles consists of NIMT FeOdots, the superparamagnetic nanoparticles use in the fields of biomedicine and biotechnology; and NIMT FeOlabel for intracellular magnetic labeling of cells. In addition, it offers magnetic resonance imaging services, including study design, in vivo, and in vitro model development. The company serves pharmaceutical and biotech companies, as well as contract research and contract manufacturing companies primarily in the United States, Europe, and Asia. Genovis AB (publ) was founded in 1999 and is based in Lund, Sweden.
genovis ab (GENO) Key Developments
Genovis AB (publ) reported consolidated and parent earnings results for the first quarter ended March 2013. For the quarter on consolidated basis, the company reported net sales of SEK 1,906,000 against SEK 944,000 for the same period a year ago. Operating loss was SEK 3,957,000 against SEK 4,005,000 for the same period a year ago. Loss attributable to shareholders in the company was SEK 3,946,000 against SEK 3,970,000 for the same period a year ago. Earnings per basic and diluted share were SEK 0.33 against loss per basic and diluted share of SEK 0.57 for the same period a year ago. Cash flow from operating activities was SEK 4,429,000 against SEK 2,871,000 for the same period a year ago. Operating loss before depreciation, amortization and impairment was SEK 3,737,000 against SEK 3,662,000 for the same period a year ago. Consolidated capital expenditure was SEK 595,000, compared to SEK 458,000 for the same period a year ago. For the quarter, the parent company reported operating income of SEK 2,839,000 against SEK 1,138,000 for the same period a year ago. Operating loss was SEK 2,903,000 against SEK 3,692,000 for the same period a year ago. Loss before taxes was SEK 4,003,000 against SEK 3,854,000 for the same period a year ago. Net loss was SEK 4,003,000 against SEK 3,854,000 for the same period a year ago. Cash flow from operating activities was SEK 3,163,000 against SEK 2,609,000 for the same period a year ago. Net sales and operating profit/loss in the parent company are attributable to the primary and only business area: sales and/or outlicensing of research-based innovations. Revenue for the period January-March was SEK 2,839,000, of which SEK 1,906,000 was attributable to sales. For the quarter, the company reported an impairment charge of SEK 1,100,000 had a negative impact on the parent company's income statement.
Genovis AB (publ) announced consolidated and standalone financial results for the fourth quarter and full year 2012. On consolidated basis, for the quarter, the company reported net sales of SEK 2,017,000 compared to SEK 1,071,000 a year ago. Operating loss before depreciation, amortization and impairment was SEK 4,335,000 compared to SEK 3,333,000 a year ago. Operating loss was SEK 8,491,000 compared to SEK 3,956,000 a year ago. Loss after financial items was SEK 8,465,000 compared to SEK 3,956,000 a year ago. Loss after tax was SEK 8,331,000 compared to SEK 3,835,000 a year ago. Loss attributable to shareholders was SEK 8,331,000 or SEK 0.70 per basic and diluted share compared to SEK 3,835,000 or SEK 0.55 per basic and diluted share a year ago. Cash flow from operating activities was SEK 3,889,000 compared to SEK 2,503,000 a year ago. On consolidated basis, for the year, the company reported net sales of SEK 6,080,000 compared to SEK 2,856,000 a year ago. Operating loss before depreciation, amortization and impairment was SEK 14,975,000 compared to SEK 12,435,000 a year ago. Operating loss was SEK 20,181,000 compared to SEK 13,745,000 a year ago. Loss after financial items was SEK 20,161,000 compared to SEK 13,758,000 a year ago. Loss after tax was SEK 19,915,000 compared to SEK 13,608,000 a year ago. Loss attributable to shareholders was SEK 19,915,000 or SEK 2.04 per basic and diluted share compared to SEK 13,608,000 or SEK 2.37 per basic and diluted share a year ago. Cash flow from operating activities was SEK 14,848,000 compared to SEK 12,150,000 a year ago. On standalone basis, for the quarter, the company reported revenue of SEK 2,464,000 compared to SEK 1,506,000 a year ago. Operating loss was SEK 5,318,000 compared to SEK 2,947,000 a year ago. Loss before taxes was SEK 8,962,000 compared to SEK 4,633,000 a year ago. Net loss for the period was SEK 8,554,000 compared to SEK 4,633,000 a year ago. Cash flow from operating activities was SEK 3,613,000 compared to SEK 1,945,000 a year ago. On standalone basis, for the year, the company reported revenue of SEK 7,095,000 compared to SEK 3,407,000 a year ago. Operating loss was SEK 16,120,000 compared to SEK 11,242,000 a year ago. Loss before taxes was SEK 20,219,000 compared to SEK 14,300,000 a year ago. Net loss for the period was SEK 19,811,000 compared to SEK 14,300,000 a year ago. Cash flow from operating activities was SEK 13,898,000 compared to SEK 10,260,000 a year ago. Net capital expenditure totaled SEK 1,324,000 compared to SEK 1,870,000 a year ago.
Genovis AB (publ), Annual General Meeting, Apr 25, 2013.

| Recently Viewed | |||
| GENO:SS | kr4.00 SEK | -0.50 | |
| Company | Last | Change |
| Bio-Rad Laboratories Inc | $113.55 USD | +1.07 |
| Life Technologies Corp | $74.24 USD | -- |
| Nanoco Group PLC | 134.50 GBp | +2.50 |
| Sigma-Aldrich Corp | $81.73 USD | +0.25 |
| Thermo Fisher Scientific Inc | $85.55 USD | +0.43 |
| View Industry Companies | ||
Industry Analysis
GENO
Industry Average
| Valuation | GENO | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 6.8x |
|
| Price/Book | 5.6x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 8.8x |
|
Post a JobJobs
- Thomasville, GA | Flowers FoodsPosted: Jun 07
- San Francisco, CA | YelpPosted: Jun 06
- San Francisco, CA | PeoplematterPosted: Jun 06
- Orlando, FL | Consult SoftPosted: May 22
Sponsored Financial Commentaries
Sponsored Links
To contact GENOVIS AB, please visit www.genovis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.








